Fresenius Invests in BioIntellisense AI Platform

“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.

Read the full article » | Posted 09-12-2019

Related Articles

• Watch a 2-minute video of Dr. Brigitte Schiller describing a paper on nocturnal home HD Posted 08-21-2026
• The Quanta Dialysis System for home HD is the first FDA 510(k) approved machine that offers high (500 mL/min) dialysate flow Posted 08-21-2026
• The American Kidney Fund’s Kidney Action Week: Future of Kidney Care is September 8-10. Posted 08-21-2026
• On August 9, CMS published “Regulatory Alignment for Predictable and Immediate Device Coverage Pathway (CMS-3487-NC) Procedural Notice Inviting Comment.” Posted 08-21-2026